Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | CTCs as a prognostic indicator in patients with newly diagnosed multiple myeloma

Ioannis Ntanasis-Stathopoulos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the results of a study which demonstrated that high levels of circulating tumor cells (CTCs) at diagnosis are predictive of adverse prognosis in patients with both transplant-eligible and transplant-ineligible multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.